1. Home
  2. STAA vs CGEM Comparison

STAA vs CGEM Comparison

Compare STAA & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STAAR Surgical Company

STAA

STAAR Surgical Company

HOLD

Current Price

$18.63

Market Cap

867.9M

Sector

Health Care

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$13.68

Market Cap

794.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STAA
CGEM
Founded
1982
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
867.9M
794.7M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
STAA
CGEM
Price
$18.63
$13.68
Analyst Decision
Hold
Strong Buy
Analyst Count
9
9
Target Price
$22.19
$30.11
AVG Volume (30 Days)
1.3M
773.4K
Earning Date
03-03-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$239,442,000.00
N/A
Revenue This Year
$27.04
N/A
Revenue Next Year
$7.27
$79.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.69
$5.68
52 Week High
$30.81
$16.74

Technical Indicators

Market Signals
Indicator
STAA
CGEM
Relative Strength Index (RSI) 50.77 49.95
Support Level $17.13 $11.43
Resistance Level $19.44 $16.74
Average True Range (ATR) 0.92 0.83
MACD 0.12 -0.16
Stochastic Oscillator 71.74 32.74

Price Performance

Historical Comparison
STAA
CGEM

About STAA STAAR Surgical Company

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: